<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Oral Antidiabetic Drugs</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
  <md:title>Oral Antidiabetic Drugs</md:title>
  <md:content-id>m00415</md:content-id>
  <md:uuid>fa3dff46-f2f3-44f8-b7d3-ddac12d342d0</md:uuid>
  </metadata>
  <content>
  <section class="learning-objectives" id="sect-00001">
  <title>Learning Outcomes</title>
  <para id="para-00001">By the end of this section, you should be able to:</para>
  <list id="list-00001">
  <item>Identify the characteristics of oral diabetes drugs.</item>
  <item>Explain the indications, actions, adverse reactions, contraindications, and interactions of oral diabetes drugs.</item>
  <item>Describe nursing implications of oral diabetes drugs.</item>
  <item>Explain the client education related to oral diabetes drugs.</item>
  </list>
  </section>
  <para id="para-00002">Oral diabetes drugs are used to treat type 2 diabetes. They are ineffective with type 1 diabetes because type 1 diabetic β cells are not functioning. These drugs lower blood glucose levels in various ways, such as stimulating insulin production from β cells, decreasing insulin resistance, slowing glucose absorption from the gastrointestinal tract, and altering the release of glucose by the liver (American Diabetes Association, n.d.-a).</para>
  <section id="sect-00002">
  <title>Sulfonylureas</title>
  <para id="para-00003"><term class="no-emphasis" id="term-00001">Sulfonylureas</term> are a group of diabetes drugs that bind to potassium channels on β cells and stimulate them to produce more insulin. They are effective in clients with diabetes who have functioning β cells. They are not effective in all clients with type 2 diabetes. Sulfonylureas may lose their effectiveness over time, requiring an increase in dosage (Costello et al., 2022). </para>
  <note class="safety-alert" id="note-00001">
  <title>Sulfonylureas</title>
  <para id="para-00005">Sulfonylureas should be used cautiously with beta blockers. Beta blockers can mask the early symptoms of hypoglycemia, such as tachycardia and tremors. Also, when taken with a sulfonylurea, a nonselective beta blocker can prevent the body from compensating for hypoglycemia, resulting in critically low levels especially when the client is sleeping (Costello et al., 2022; Dimakos et al., 2023).</para>
  </note>
  <section id="sect-00003">
  <title>First-Generation Short-Acting Sulfonylureas</title>
  <para id="para-00006"><term class="no-emphasis" id="term-00002">First-generation short-acting sulfonylureas</term> lower blood glucose levels by causing the pancreas to produce insulin. These drugs were previously used along with diet, exercise, and, at times, other diabetes drugs to control type 2 diabetes; however, they have been discontinued for use in the United States with the development of second-generation sulfonylureas (Costello et al., 2022).</para>
  </section>
  <section id="sect-00004">
  <title>Second-Generation Sulfonylureas</title>
  <para id="para-00007"><term class="no-emphasis" id="term-00003">Second-generation sulfonylureas</term> increase insulin secretion through the pancreatic β cells. They are used along with diet, exercise, and sometimes other diabetes drugs to control glucose levels. Second-generation sulfonylureas typically have lower dosing, a longer duration of action, and fewer side effects than first-generation sulfonylureas. These drugs are metabolized in the liver and excreted in the urine. They should be used cautiously in clients with hepatic and renal impairment. Dosage usually begins with a low dose and is increased based on the client’s glucose control needs (Costello et al., 2022).</para>
  <section id="sect-00005">
  <title>Glipizide</title>
  <para id="para-00008"><term class="no-emphasis" id="term-00004">Glipizide</term> is a second-generation sulfonylurea that stimulates the pancreas to produce insulin, thereby lowering blood glucose levels. Glipizide is used along with diet and exercise to improve glucose homeostasis in adults with type 2 diabetes. Glipizide comes in tablet form and should be taken 30 minutes before the first meal of the day. It also comes in an extended-release form. The extended-release form should not be chewed, crushed, or broken and should be swallowed whole. The extended-release form should be taken with the first meal of the day. </para>
  <para id="para-00009">Adverse effects of glipizide include headache, irritability, sweating, tachycardia, dizziness, nausea, blurred vision, feeling shaky, hypoglycemia, drowsiness, tremor, insomnia, myalgia, weight gain, and paresthesia. Serious adverse effects include agranulocytosis, aplastic anemia, thrombocytopenia, hepatic failure, and syndrome of inappropriate antidiuretic hormone (SIADH). Liver enzymes should be monitored closely when using this drug (National Library of Medicine, 2022b).</para>
  </section>
  <section id="sect-00006">
  <title>Glyburide</title>
  <para id="para-00010"><term class="no-emphasis" id="term-00005">Glyburide</term> is a second-generation sulfonylurea that stimulates the pancreas to produce insulin. Glyburide is used along with diet and exercise to control glucose levels. It comes in tablet form and is taken once or twice daily. Adverse effects include indigestion, flatulence, arthralgia (joint pain), blurred vision, dizziness, hypoglycemia, and irritability. This medication should be used cautiously with beta blockers because severe hypoglycemia may occur when they are taken together (National Library of Medicine, 2022c).</para>
  </section>
  <section id="sect-00007">
  <title>Glimepiride</title>
  <para id="para-00011"><term class="no-emphasis" id="term-00006">Glimepiride</term>, like glyburide and glipizide, is a second-generation sulfonylurea used along with diet and exercise to control blood glucose levels in the body. It is often used along with insulin to treat type 2 diabetes. Glimepiride comes in tablet form and is taken once daily with the first meal of the day. Adverse effects include dizziness, nausea, jaundice, upper abdominal pain, diarrhea, hypoglycemia, blurred vision, weight gain, and elevated serum alanine aminotransferase (ALT) levels (National Library of Medicine, 2022a; DailyMed, <emphasis effect="italics">Glimepiride</emphasis>, 2021).</para>
  </section>
  </section>
  </section>
  <section id="sect-00008">
  <title>Non-Sulfonylurea Biguanides</title>
  <para id="para-00012"><term class="no-emphasis" id="term-00007">Non-sulfonylurea biguanides</term> are a group of oral diabetes drugs that prevent the production of glucose in the liver. They improve the body’s sensitivity to insulin and reduce the amount of glucose absorbed by the intestines. Non-sulfonylurea biguanides are used to treat type 2 diabetes (Corcoran &amp; Jacobs, 2022).</para>
  <para id="para-00013"><term class="no-emphasis" id="term-00008">Metformin</term> is a non-sulfonylurea biguanide. It is used to treat type 2 diabetes along with diet, exercise, and sometimes other diabetes drugs or insulin. Metformin comes as an immediate release tablet, an extended-release tablet, and an oral solution. Adverse effects include dizziness, headache, weakness, hypoglycemia, palpitations, flushing, nausea, vomiting, diarrhea, and flatulence. Metformin should be used cautiously in elderly clients and in clients with renal and hepatic impairments. Clients should not drink alcohol while taking metformin (Corcoran &amp; Jacobs, 2022).</para>
  <note class="safety-alert" id="note-00002">
  <title>Metformin and Contrast Dye</title>
  <para id="para-00015">Contrast dye can increase the risk of lactic acidosis (when lactic acid production exceeds lactic acid clearance in the body) in clients who are taking metformin and have decreased renal function. Metformin should be withheld 24 hours prior to and for 48 hours after contrast dye administration if the estimated glomerular filtration rate (eGFR) is less than 30 mL/min (Yale School of Medicine, 2022).</para>
  </note>
  <note class="black-box" id="note-00003">
  <para id="para-00016"><emphasis effect="bold">Metformin</emphasis></para>
  <para id="para-00017">Lactic acidosis is a rare but potentially severe consequence of therapy with the non-sulfonylurea biguanide metformin.</para>
  </note>
  </section>
  <section id="sect-00009">
  <title>Alpha-Glucosidase Inhibitors</title>
  <para id="para-00018"><term class="no-emphasis" id="term-00009">Alpha-glucosidase inhibitors</term> lower blood glucose levels by inhibiting enzymes such as amylase, maltase, and sucrose in the GI tract, thus delaying the digestion and intestinal absorption of carbohydrates (Akmal &amp; Wadhwa, 2022).</para>
  <section id="sect-00010">
  <title>Acarbose</title>
  <para id="para-00019"><term class="no-emphasis" id="term-00010">Acarbose</term> was the prototype alpha-glucosidase inhibitor. It delays digestion and absorption of carbohydrates to diminish the increase in blood glucose levels after meals. Acarbose is rapid acting and peaks in 1 hour. It is metabolized by the GI tract and excreted in the urine and feces. Adverse effects include nausea, vomiting, diarrhea, malabsorption, leukopenia, thrombocytopenia, and anemia. It is contraindicated for use in clients with severe renal and hepatic impairments (Feingold, 2022).</para>
  </section>
  <section id="sect-00011">
  <title>Miglitol</title>
  <para id="para-00020"><term class="no-emphasis" id="term-00011">Miglitol</term> slows the digestion of carbohydrates. It is used in combination with diet, exercise, and sometimes other drugs to control blood glucose levels. It is rapidly absorbed and excreted in the urine. Adverse effects include bloating, flatulence, diarrhea, and abdominal pain or cramping (Feingold, 2022).</para>
  </section>
  </section>
  <section id="sect-00012">
  <title>Thiazolidinediones</title>
  <para id="para-00021"><term class="no-emphasis" id="term-00012">Thiazolidinediones</term> lower blood glucose levels by decreasing insulin resistance. They are referred to as “<term class="no-emphasis" id="term-00013">glitazones</term>” or “<term class="no-emphasis" id="term-00014">insulin sensitizers</term>” (Feingold, 2022; Eggleton &amp; Jialal, 2023).</para>
  <para id="para-00022">Pioglitazone hydrochloride is a thiazolidinedione that is used along with diet and exercise to decrease blood glucose levels. It works to enhance the body’s response to insulin, thereby decreasing glucose in the blood. Adverse effects include muscle pain, weight gain, sore throat, blurred vision, and tooth problems. Pioglitazone hydrochloride is contraindicated in those with liver impairment (Feingold, 2022).</para>
  </section>
  <section id="sect-00013">
  <title>Meglitinides</title>
  <para id="para-00023">Meglitinides lower blood glucose levels by stimulating the pancreas to secrete insulin. This class of drug has the potential to produce rapid, short-lived insulin output in those with type 2 diabetes. Because of the rapid onset and short duration of action with these drugs, they should be administered 1–30 minutes prior to meals (Feingold, 2022).</para>
  <para id="para-00024">Repaglinide is a meglitinide that works in clients with type 2 diabetes by closing potassium channels in the pancreatic beta cells, thereby increasing insulin secretion, which lowers glucose levels in the blood. It is absorbed through the GI tract and peaks in 1–1.5 hours. Metabolism occurs in the liver, and it is excreted in the urine and feces. Adverse effects include GI upset, upper respiratory infections, and hypoglycemia. It is contraindicated for use in those with type 1 diabetes and those with diabetic ketoacidosis (Feingold, 2022).</para>
  </section>
  <section id="sect-00014">
  <title>Dipeptidyl Peptidase 4 (DDP 4) Inhibitors</title>
  <para id="para-00025">Dipeptidyl peptidase 4 inhibitors block the action of dipeptidyl peptidase 4, an enzyme that destroys incretin. Incretin helps the body produce insulin only when it is needed to reduce the excess amount of glucose being produced by the liver. DDP 4 inhibitors are used to treat type 2 diabetes (Kasina &amp; Baradhi, 2022).</para>
  <section id="sect-00015">
  <title>Sitagliptin</title>
  <para id="para-00026">Sitagliptin is a DDP 4 inhibitor used to treat type 2 diabetes. It is rapidly absorbed, peaks in 1–4 hours, and has a 12-hour half-life. It is mainly excreted through the urine. Adverse effects include runny nose, sore throat, headache, and upper respiratory infections. Hypoglycemia may occur when used in combination with other drugs. Sitagliptin is contraindicated in those with congestive heart failure (Zhou et al., 2019).</para>
  </section>
  <section id="sect-00016">
  <title>Linagliptin</title>
  <para id="para-00027">Linagliptin, like sitagliptin, is a DDP 4 inhibitor used to treat type 2 diabetes. It is rapidly absorbed and long acting. It peaks in 1.5 hours and has a 12-hour half-life. Adverse effects include bloating, skin rash, stomach pain, back pain, and joint pain. It should be used cautiously in those with hypersensitivity, exfoliative dermatitis, or bronchial hypersensitivity (Gharabaghi et al., 2022).</para>
  </section>
  </section>
  <section id="sect-00017">
  <title>Selective Sodium Glucose Transporter 2 (SGLT2)</title>
  <para id="para-00028">Selective sodium glucose transporter 2 drugs are used to treat clients with type 2 diabetes. SGLT2 drugs lower blood glucose levels by blocking the reabsorption of glucose in the kidneys and promoting the excretion of glucose in the urine (Padda et al., 2022).</para>
  <section id="sect-00018">
  <title>Dapagliflozin</title>
  <para id="para-00029">Dapagliflozin is an SGLT2 drug that reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion. It is rapidly absorbed and peaks in 2 hours. It is metabolized in the liver and excreted mainly in the urine. Adverse effects include increased urination, skin rash, dehydration, hypotension, back pain, and genital infections including UTIs. It is contraindicated in those with renal impairment (Dhillon, 2019).</para>
  <section id="sect-00019">
  <title>Empagliflozin</title>
  <para id="para-00030">Empagliflozin is an SGLT2 drug that is rapidly absorbed. It peaks in 1.5 hours. Empagliflozin is metabolized by the liver and excreted mainly in the urine. Adverse effects include increased urination, bladder pain, painful urination, vaginal irritation or discharge, and pain during intercourse. It is contraindicated in those with renal impairment (Sizar et al., 2022).</para>
  </section>
  </section>
  <section id="sect-00020">
  <title>Fixed Combination Oral Diabetes Drugs</title>
  <para id="para-00031">Fixed combination oral diabetes drug therapy may be required in the control of type 2 diabetes. Combination oral diabetes drug therapy is used when monotherapy, diet, and exercise alone cannot control blood glucose levels. Although in the past these drugs were taken as separate tablets, several fixed-dose single-tablet combinations have been manufactured (Kalra et al., 2020).</para>
  <note class="link-to-learning" id="note-00004">
  <title>New in Oral Diabetes Medicines: Non-Insulin Injectables</title>
  <media alt="atoms_isotopes">
  <iframe width="560" height="315" src="https://openstax.org/r/oraldiabetes"/>
  </media>
  <para id="para-00033">In this video, Lisa Kroon, a Doctor of Pharmacy, describes general treatments for glycemic control (hyperglycemia) in people with type 2 diabetes.</para>
  </note>
  <section id="sect-00021">
  <title>Glyburide-Metformin</title>
  <para id="para-00034">Glyburide-metformin is a combination of a second-generation sulfonylurea and a non-sulfonylurea biguanide. It is used in conjunction with diet and exercise for clients with type 2 diabetes that was not controlled with a monotherapy diabetes drug. Dosing is a combined tablet of 1.25 mg glyburide and 250 mg metformin one to two times daily. The maximum dose is 20 mg glyburide and 2000 mg metformin daily. It is not recommended for use in children. Adverse effects include blurred vision, drowsiness, excessive hunger, headache, nausea, nervousness, sore throat, and unusual tiredness. Glyburide-metformin is contraindicated in those with severe renal and liver impairment. Those with congestive heart failure should use it cautiously because this drug may increase the risk of myocardial infarction (Shuster et al., 2020).</para>
  </section>
  <section id="sect-00022">
  <title>Sitagliptin-Metformin</title>
  <para id="para-00035">Sitagliptin-metformin is a fixed-dose combination diabetes drug that combines a dipeptidyl peptidase 4 inhibitor and a non-sulfonylurea biguanide. Sitagliptin-metformin is used to treat type 2 diabetes when the diet, exercise, and monotherapy diabetes drugs were ineffective. The recommended starting dose in clients not currently treated with metformin is 50 mg sitagliptin and 500 mg metformin HCl twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. The starting dose in clients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. For clients taking metformin HCl 850 mg twice daily, the recommended starting dose of sitagliptin-metformin is 50 mg sitagliptin and 1000 mg metformin HCl twice daily. The maximum recommended daily dose is 100 mg of sitagliptin and 2000 mg of metformin hydrochloride (HCl). Adverse effects include diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, hypoglycemia, EKG changes, pancreatitis, acute renal failure, myalgia, and pain in extremity (DailyMed, <emphasis effect="italics">Sitagliptin</emphasis>, 2023; He et al., 2021).</para>
  </section>
  <section id="sect-00023">
  <title>Liraglutide-Insulin Degludec</title>
  <para id="para-00036">Liraglutide-insulin degludec is a fixed-dose combination of liraglutide and insulin degludec. It is used to treat type 2 diabetes when diet, exercise, and drug monotherapy were ineffective. It comes in a subcutaneous pen similar to an insulin pen. The pen is a combined dose of insulin degludec 50 units and liraglutide 1.8 mg. Adult and <term class="no-emphasis" id="term-00015">pediatric dosing</term> is based on the client’s blood glucose level and must be determined by the health care provider. Adverse effects include bloating, blurred vision, chills, confusion, constipation, dry mouth, headache, hives, increased hunger, lightheadedness, muscle aches, nausea, sweating, tachycardia, and trouble swallowing. It is contraindicated in those with hypoglycemia, pancreatitis, and hypersensitivity (DailyMed <emphasis effect="italics">Victoza, Liraglutide injection</emphasis>, 2023).</para>
  <note class="unfolding-casestudy" id="note-00005">
  <para id="para-00037"><emphasis effect="bold">Part B</emphasis></para>
  <para id="para-00038">Read the following clinical scenario to answer the questions that follow. This case study is a follow-up to Case Study Part A.</para>
  <table class="vertically-tight" id="table-00001">
  <tgroup cols="3">
  <colspec colnum="1" colname="c1" colwidth="1*"/>
  <colspec colnum="2" colname="c2" colwidth="1*"/>
  <colspec colnum="3" colname="c3" colwidth="1*"/>
  <tbody>
  <row>
 <entry valign="top" align="left" namest="c1" nameend="c3">Alaina Sanders was diagnosed with type 2 diabetes, and the health care provider prescribed extended-release glipizide 5 mg orally and lifestyle modifications. The client returns to her health care provider’s office today for a 6-month follow-up appointment after starting drug treatment and lifestyle modifications.<newline count="2"/>
<emphasis effect="bold">Laboratory Results</emphasis><newline/>
  Glycosylated hemoglobin<newline count="2"/>
  <emphasis effect="bold">6 Months Ago</emphasis><newline/>
  7.8%<newline count="2"/>
  <emphasis effect="bold">Today</emphasis><newline/>
  6.9%</entry>
  </row>
  <row>
  <entry valign="top" align="center" namest="c1" nameend="c2"><span class="blue-text"><emphasis effect="bold"><span class="blue-text">Vital Signs</span></emphasis></span></entry>
  <entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Physical Examination</span></emphasis></entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="italics">Temperature:</emphasis></entry>
  <entry valign="top" align="left">97.4°F</entry>
  <entry valign="top" align="left" morerows="6"><list list-type="bulleted" id="list-00002">
  <item><emphasis effect="italics">Head, eyes, ears, nose, throat (HEENT):</emphasis> Within normal limits</item>
  <item><emphasis effect="italics">Cardiovascular:</emphasis> No jugular vein distention or peripheral edema. S1, S2 heard on auscultation.</item>
  <item><emphasis effect="italics">Respiratory:</emphasis> Breath sounds clear bilaterally</item>
  <item><emphasis effect="italics">GI:</emphasis> Abdomen soft, nontender, nondistended</item>
  <item><emphasis effect="italics">GU:</emphasis> Within normal limits</item>
  <item><emphasis effect="italics">Neurological:</emphasis> Within normal</item>
  <item><emphasis effect="italics">Integumentary:</emphasis> No wounds noted; skin appropriate for age</item></list></entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="italics">Blood pressure:</emphasis></entry>
  <entry valign="top" align="left">108/72 mm Hg</entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="italics">Heart rate:</emphasis></entry>
  <entry valign="top" align="left">84 beats/min</entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="italics">Respiratory rate:</emphasis></entry>
  <entry valign="top" align="left">18 breaths/min</entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="italics">Oxygen saturation:</emphasis></entry>
  <entry valign="top" align="left">97% on room air</entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="italics">Height:</emphasis></entry>
  <entry valign="top" align="left">5’5”</entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="italics">Weight:</emphasis></entry>
  <entry valign="top" align="left">173 lb</entry>
  </row>
  </tbody>
  </tgroup>
  </table>
  <exercise id="exer-00001"><problem id="prob-00001"><para id="para-00039"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec1_UCSQ3"/></para></problem></exercise>
  <exercise id="exer-00002"><problem id="prob-00002"><para id="para-00040"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec2_UCSQ4"/></para></problem></exercise>
  </note>
  </section>
  </section>
  </section>
  <section id="sect-00024">
  <title>Hypoglycemia Drugs</title>
  <para id="para-00041"><term class="no-emphasis" id="term-00016">Hypoglycemia drugs</term> raise blood glucose levels. These drugs are used to treat severe hypoglycemia and hypoglycemic reactions that are often associated with diabetes. They are used after conservative measures to treat severe hypoglycemia are ineffective (Mathew &amp; Thoppil, 2022).</para>
  <section id="sect-00025">
  <title>Glucagon</title>
  <para id="para-00042"><term class="no-emphasis" id="term-00017">Glucagon</term> is a hormone secreted by alpha (α) cells of the islets of Langerhans in the pancreas. Glucagon increases blood glucose levels by stimulating glycogen breakdown in the liver. Peak time is 15 minutes after dosing. Glucagon comes as an injectable and as a nasal spray. Adult and <term class="no-emphasis" id="term-00018">pediatric dosing</term> is based on the client’s age and weight. Glucagon is used when the client is semiconscious, unconscious, or unable to ingest sugar-containing food. Blood glucose levels should be reassessed 15 minutes after administering this drug. Adverse effects include nausea, vomiting, and temporary tachycardia. Glucagon is contraindicated in clients with hypersensitivity and with known <term id="term-00019">pheochromocytoma</term> (Morris &amp; Baker, 2022).</para>
  </section>
  <section id="sect-00026">
  <title>Diazoxide</title>
  <para id="para-00043"><term class="no-emphasis" id="term-00020">Diazoxide</term> is a non-diuretic <term class="no-emphasis" id="term-00021">benzothiadiazine</term> and works by inhibiting insulin release from the pancreas by opening potassium channels in the beta cell membrane. It is used to treat hypoglycemia in clients with hyperinsulinemia. This drug is also a vasodilator and used to treat hypertensive emergencies. It is rapidly absorbed and highly protein bound. Diazoxide is metabolized by the liver and mainly excreted by the kidneys. The usual adult daily oral dosage is 3–8 mg/kg, divided into two or three equal doses every 8 or 12 hours. Its onset is 1 hour, and its duration is 8 hours. Adverse effects include anorexia, nausea, vomiting, abdominal pain, tachycardia, palpitations, and increased uric acid levels. Diazoxide is contraindicated in clients with a hypersensitivity to sulfonamide and thiazide diuretics (Chen et al., 2021).</para>
  </section>
  <para id="para-00044"><link target-id="table-00002" document="m00415"/> lists common oral diabetes drugs and typical routes and dosing for adult clients (with <term class="no-emphasis" id="term-00022">pediatric exception note for metformin</term>).</para>
  <table class="vertically-tight" id="table-00002">
  <tgroup cols="2">
  <colspec colnum="1" colname="c1" colwidth="1*"/>
  <colspec colnum="2" colname="c2" colwidth="2*"/>
 <thead>
   <row>
  <entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
  <entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Routes and Dosage Ranges</span></emphasis></entry>
  </row>
</thead>
  <tbody>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00023">Acarbose</term> (<term class="no-emphasis" id="term-00036">Precose</term>)</entry>
  <entry valign="top" align="left">25 mg orally 3 times daily with meals.<newline/>
  <emphasis effect="italics">Maximum dose: </emphasis>300 mg daily.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00024">Dapagliflozin</term> (<term class="no-emphasis" id="term-00037">Farxiga</term>)</entry>
  <entry valign="top" align="left">Dosage is adjusted based on estimated glomerular filtration rate (eGFR):<newline/>
  <list list-type="bulleted" id="list-00003">
  <item><emphasis effect="italics">eGFR 45 or greater:</emphasis> 5–10 mg orally once daily.</item>
  <item><emphasis effect="italics">eGFR 25 to less than 45:</emphasis> 10 mg orally once daily.</item>
  <item><emphasis effect="italics">eGFR less than 25:</emphasis> Not recommended.</item>
  </list>
  </entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00025">Empagliflozin</term> (<term class="no-emphasis" id="term-00038">Jardiance</term>)</entry>
  <entry valign="top" align="left">10 mg orally once daily.<newline/>
  <emphasis effect="italics">Maximum dose:</emphasis> 25 mg daily.<newline/>
  Data are insufficient to provide a dosage recommendation in clients who have<newline/>
  type 2 diabetes mellitus and established cardiovascular disease with an eGFR less than 30 mL/min/1.73 m<sup>2</sup> or heart failure with an eGFR less than 20 mL/min/1.73 m<sup>2</sup>.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00026">Glipizide (Glucotrol, Glucotrol XL)</term></entry>
  <entry valign="top" align="left">5 mg orally daily 30 minutes before breakfast.<newline/>
  <emphasis effect="italics">Maximum dose:</emphasis> 40 mg daily.<newline/>
  <emphasis effect="italics">Extended release:</emphasis> Once daily with breakfast.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00027">Glyburide/metformin</term> (<term class="no-emphasis" id="term-00039">Glucovance</term>)</entry>
  <entry valign="top" align="left">1.25 mg glyburide/250 mg metformin orally daily. Titrate 2 weeks after initial dosing up to 1.25 mg glyburide/250 mg metformin orally every 12 hours. <emphasis effect="italics">Maximum dose:</emphasis> 20 mg glyburide/2000 mg metformin orally daily.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00028">Liraglutide/insulin degludec (Xultrophy)</term></entry>
  <entry valign="top" align="left">10 units insulin degludec/3.6 mg of liraglutide subcutaneously once daily. <newline/><emphasis effect="italics">Maximum dose:</emphasis> 50 units insulin degludec/1.8 mg liraglutide subcutaneously daily.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00029">Metformin</term> (<term class="no-emphasis" id="term-00040">Glucophage</term>, <term class="no-emphasis" id="term-00041">Glucophage XR</term>)</entry>
  <entry valign="top" align="left"><emphasis effect="bold">Immediate Release</emphasis><newline/>
  <emphasis effect="italics">Adults:</emphasis> 500–1000 mg orally twice daily.<newline/>
  <emphasis effect="italics">Maximum dose:</emphasis> 2000 mg daily.<newline/>
  <emphasis effect="italics">Children (the only oral diabetes drug that is safe for use in children 10–17 years of age):</emphasis> 500 mg orally twice daily.<newline/>
  <emphasis effect="italics">Maximum dose: </emphasis>2000 mg daily in divided doses.<newline/>
  <emphasis effect="bold">Extended Release</emphasis><newline/>
  <emphasis effect="italics">Adults:</emphasis> 250–500 mg once daily with evening meal; increase dose by 500 mg/week on the basis of glycemic control and tolerability.<newline/> <emphasis effect="italics">Maximum dose:</emphasis> 2000 mg/day.<newline/>
  <emphasis effect="italics">Children: </emphasis>Health care provider should determine dose based on body surface area and glucose target range.<newline/>
  <emphasis effect="bold">Oral Solution</emphasis><newline/>
  <emphasis effect="italics">Adults and children: </emphasis>500 mg/5 mL daily up to a maximum dose of 2000 mg/day.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00030">Miglitol</term> (<term class="no-emphasis" id="term-00042">Glyset</term>)</entry>
  <entry valign="top" align="left">25 mg orally 3 times daily at the start of each meal. <newline/>Maximum dose: 200 mg 3 times daily.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00031">Pioglitazone</term> (<term class="no-emphasis" id="term-00043">Actos</term>)</entry>
  <entry valign="top" align="left">15–30 mg orally once daily.<newline/>
  <emphasis effect="italics">Maximum dose:</emphasis> 45 mg daily.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00032">Repaglinide (Prandin)</term></entry>
  <entry valign="top" align="left">0.5–4 mg orally 3 to 4 times daily, 15–30 minutes before meals. <newline/>Maximum dose: 16 mg daily.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00033">Sitagliptin</term> (<term class="no-emphasis" id="term-00044">Januvia</term>)</entry>
  <entry valign="top" align="left">100 mg orally daily.<newline/>
  <emphasis effect="italics">For patients with an eGFR &lt;45 mL/min/1.73 m<sup>2</sup> to >90 mL/min/1.73 m<sup>2</sup></emphasis>: No dosage adjustment required.<newline/>
  <emphasis effect="italics">For patients with moderate renal impairment (eGFR >30 mL/min/1.73 m<sup>2</sup> to &lt;45 mL/min/1.73 m<sup>2</sup>):</emphasis> 50 mg once daily.<newline/>
  <emphasis effect="italics">For patients with severe renal impairment (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis:</emphasis> 25 mg once daily.<newline/>
  May be administered without regard to the timing of dialysis.</entry>
  </row>
  <row>
  <entry valign="top" align="center"><term class="no-emphasis" id="term-00034">Sitagliptin/metformin (Janumet)</term></entry>
  <entry valign="top" align="left"><emphasis effect="italics">Clients not currently treated with metformin: </emphasis>Initial dose: 50 mg sitagliptin/500 mg metformin orally twice daily with gradual escalation.<newline/>
  <emphasis effect="italics">Clients already treated with metformin:</emphasis> Initial dose: 50 mg sitagliptin twice daily and the dose of metformin already being taken.<newline/>
  <emphasis effect="italics">Maximum dose:</emphasis> 100 mg sitagliptin/2000 mg metformin orally daily.</entry>
  </row>
  </tbody>
  </tgroup>
  <caption><emphasis effect="bold">Drug Emphasis Table: Oral Diabetes Drugs</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
  </table>
  </section>
  <section id="sect-00027">
  <title>Adverse Effects and Contraindications</title>
  <para id="para-00045">Common adverse effects of oral diabetes drugs include gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal discomfort), hypoglycemia (symptoms include dizziness, shakiness, sweating/chills, clammy skin, feeling faint, agitation, confusion, blurred or impaired vision), fluid retention, weight gain, and headache.</para>
  <para id="para-00046">Contraindications include hypersensitivity to the drug or any of its components, severe kidney disorders (as most of these drugs are excreted in the urine and can further impair renal function), hepatic insufficiency (as most of these drugs are metabolized by the liver and can result in further impaired hepatic function), and disorders with fluid retention (such as heart failure and renal failure, as these drugs can cause additional fluid retention and volume overload).</para>
  <para id="para-00047"><link target-id="table-00003" document="m00415"/> is a drug prototype table for oral diabetes drugs featuring Metformin. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00035">pediatric dosage</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
  <table class="vertically-tight" id="table-00003">
  <tgroup cols="2">
  <colspec colnum="1" colname="c1" colwidth="1*"/>
  <colspec colnum="2" colname="c2" colwidth="1*"/>
  <tbody>
  <row>
  <entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
  Non-sulfonylurea biguanide<newline count="2"/>
  <emphasis effect="bold">Mechanism of Action</emphasis><newline/>
  Decreases intestinal absorption of glucose and improves insulin sensitivity by increasing glucose uptake</entry>
  <entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline count="2"/>
  <emphasis effect="bold">Immediate Release</emphasis><newline/>
  <emphasis effect="italics">Adults:</emphasis> 500–1,000 mg orally once daily.<newline/>
  <emphasis effect="italics">Maximum dose:</emphasis> 2,000 mg daily.<newline/>
  <emphasis effect="italics">Children (the only oral diabetes drug that is safe for use in children 10–17 years of age):</emphasis> 500 mg orally twice daily. <emphasis effect="italics">Maximum dose:</emphasis> 2,000 mg daily in divided doses.<newline count="2"/>
  <emphasis effect="bold">Extended Release</emphasis><newline/>
  <emphasis effect="italics">Adults:</emphasis> 250–500 mg once daily with evening meal; increase dose by 500 mg/week on the basis of glycemic control and tolerability; maximum dose: 2000 mg/day.<newline/>
  <emphasis effect="italics">Children: </emphasis>Health care provider should determine dose based on body surface area and glucose target range.<newline count="2"/>
  <emphasis effect="bold">Oral Solution</emphasis><newline/>
  <emphasis effect="italics">Adults and children: </emphasis>500 mg/5 mL daily up to a maximum dose of 2000 mg/day.</entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
  To control hyperglycemia in those with type 2 diabetes<newline count="2"/>
  <emphasis effect="bold">Therapeutic Effects</emphasis><newline/>
  Decreases glucose production in the liver by reducing gluconeogenesis<newline/>
  Reduces glucose absorption from the intestines</entry>
  <entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
  Alcohol<newline/>
  Dolutegravir<newline/>
  Ginseng<newline/>
  Psyllium<newline/>
  Contrast dye<newline count="2"/>
  <emphasis effect="bold">Food Interactions</emphasis><newline/>
  Fiber-rich foods<newline/>
  Grapefruit juice<newline/>
  Guar gum</entry>
  </row>
  <row>
  <entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
  Dizziness/weakness<newline/>
  Headache<newline/>
  Hypoglycemia<newline/>
  Palpitations<newline/>
  Flushing<newline/>
  Nausea/vomiting/diarrhea/flatulence<newline/>
  Abdominal pain<newline/>
  Weight loss<newline/>
  Vitamin B<sub>12</sub> deficiency</entry>
  <entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
  Renal and hepatic impairment<newline/>
  Metabolic acidosis<newline/>
  Megaloblastic anemia<newline/>
  History of myocardial infarction<newline count="2"/>
  Caution:<newline/>
  Monitor closely for signs of hypoglycemic reaction; use cautiously in elderly with renal and hepatic impairments</entry>
  </row>
  </tbody>
  </tgroup>
  <caption>Drug Prototype Table: Metformin (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
  </table>
  </section>
  <section id="sect-00028">
  <title>Nursing Implications</title>
  <para id="para-00048">The nurse should do the following for clients who are taking oral diabetes drugs:</para>
  <list list-type="bulleted" id="list-00004">
  <item>Assess the client’s knowledge about diabetes, signs and symptoms, and treatment and clarify any gaps in knowledge.</item>
  <item>Monitor blood glucose levels as ordered and as needed when symptoms of hypoglycemia/hyperglycemia are present.</item>
  <item>Provide client teaching regarding how the drug is administered and when to call the health care provider. See below for client teaching guidelines.</item>
  </list>
  <note class="client-teaching" id="note-00006">
  <title>The client taking an oral diabetes drug should:</title>
  <list list-type="bulleted" id="list-00005">
  <item>Report symptoms of hypoglycemia such as headache, nervousness, sweating, clammy skin, tremor, and tachycardia.</item>
  <item>Report symptoms of hyperglycemia such as increased thirst, increased urine output, hot/dry skin, and sweet fruity breath odor, and ketones in urine.</item>
  <item>Keep 15 grams of carbohydrates on hand in case of a hypoglycemic reaction. Orange juice, graham crackers, and hard candy are appropriate carbohydrate choices during hypoglycemia.</item>
  <item>Show family members and their support system how to administer glucagon during a hypoglycemic reaction if the client cannot eat or drink or is unconscious.</item>
  <item>Keep a blood glucose journal for tracking blood glucose levels.</item>
  <item>Make lifestyle modifications as directed by their health care provider, such as diet, exercise, and weight loss, to help control blood glucose levels.</item>
  </list>
  <para id="para-00050"><emphasis effect="bold">The client taking an oral diabetes drug <emphasis effect="italics">should</emphasis> <emphasis effect="italics">not: </emphasis></emphasis></para>
  <list list-type="bulleted" id="list-00006">
  <item>Drink alcohol with oral diabetes agents because it may impair hepatic function.</item>
  </list>
  </note>
  </section>
  <section class="chapter-summary" id="sect-00029">
  <para id="para-00051">This chapter focused on managing diabetes with the use of drugs and insulin products. Type 1, type 2, and gestational diabetes were defined, along with the importance of recognizing the difference between hypoglycemia and hyperglycemia. Specific diagnostic tests for diabetes were described. Disease prevention was briefly discussed. </para>
  <para id="para-00052">Common diabetic drugs were covered in this chapter. Insulin was defined, and types of insulin were discussed. Insulin administration sites were also presented. Additional drug classifications covered included non-insulin injectable drugs, oral drugs, and drugs to treat hypoglycemic reactions. </para>
  </section>
  <section class="review-questions" id="sect-00030">
  <title>Review Questions</title>
  <exercise id="exer-00003"><problem id="prob-00003"><para id="para-00053"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec1_RQ1"/></para></problem></exercise>
  <exercise id="exer-00004"><problem id="prob-00004"><para id="para-00054"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec2_RQ2"/></para></problem></exercise>
  <exercise id="exer-00005"><problem id="prob-00005"><para id="para-00055"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec2_RQ3"/></para></problem></exercise>
  <exercise id="exer-00006"><problem id="prob-00006"><para id="para-00056"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec2_RQ4"/></para></problem></exercise>
  <exercise id="exer-00007"><problem id="prob-00007"><para id="para-00057"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec2_RQ5"/></para></problem></exercise>
  <exercise id="exer-00008"><problem id="prob-00008"><para id="para-00058"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec1_RQ6"/></para></problem></exercise>
  <exercise id="exer-00009"><problem id="prob-00009"><para id="para-00059"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec2_RQ7"/></para></problem></exercise>
  <exercise id="exer-00010"><problem id="prob-00010"><para id="para-00060"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec2_RQ8"/></para></problem></exercise>
  <exercise id="exer-00011"><problem id="prob-00011"><para id="para-00061"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec3_RQ9"/></para></problem></exercise>
  <exercise id="exer-00012"><problem id="prob-00012"><para id="para-00062"><link class="os-embed" url="#exercise/PHAR_Ch28_Sec3_RQ10"/></para></problem></exercise>
  </section>
  <section class="references" id="sect-00031">
  <para id="para-00063">Akmal, M., &amp; Wadhwa, R. (2022). <emphasis effect="italics">Alpha glucosidase inhibitors</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK557848/</para>
  <para id="para-00064">Alvarez, S., Coffey, R., &amp; Algotar, A.M. (2023). <emphasis effect="italics">Prediabetes</emphasis>. StatPearls https://www.ncbi.nlm.nih.gov/books/NBK459332/ </para>
  <para id="para-00065">American Diabetes Association. (n.d.-a). <emphasis effect="italics">Diagnosis</emphasis>. https://diabetes.org/diabetes/a1c/diagnosis </para>
  <para id="para-00066">American Diabetes Association. (n.d.-b). <emphasis effect="italics">Hyperglycemia (high blood glucose).</emphasis> https://diabetes.org/healthy-living/medication-treatments/blood-glucose-testing-and-control/hyperglycemia</para>
  <para id="para-00067">American Diabetes Association. (n.d.-c). <emphasis effect="italics">Hypoglycemia (low blood glucose)</emphasis>. https://diabetes.org/healthy-living/medication-treatments/blood-glucose-testing-and-control/hypoglycemia</para>
  <para id="para-00068">American Diabetes Association. (n.d.-d). <emphasis effect="italics">Insulin and other injectables</emphasis>. https://diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-basics</para>
  <para id="para-00069">Campbell, A. (2021). <emphasis effect="italics">Non-insulin injectable diabetes medications.</emphasis> https://www.diabetesselfmanagement.com/blog/non-insulin-injectable-diabetes-medications/</para>
  <para id="para-00070">Centers for Disease Control and Prevention. (n.d.-a.). <emphasis effect="italics">Prevalence of diagnosed diabetes. </emphasis>https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-diabetes.html</para>
  <para id="para-00071">Centers for Disease Control and Prevention. (n.d.-b.). <emphasis effect="italics">Type 2 diabetes. </emphasis>https://www.cdc.gov/diabetes/basics/type2.html</para>
  <para id="para-00072">Centers for Disease Control and Prevention. (n.d.-c) <emphasis effect="italics">The facts, stats, and impacts of diabetes. </emphasis>https://www.cdc.gov/diabetes/library/spotlights/diabetes-facts-stats.html</para>
  <para id="para-00073">Centers for Disease Control and Prevention. (2022a). <emphasis effect="italics">CDC clinical reminder: Insulin pens must never be used for more than one person.</emphasis> https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</para>
  <para id="para-00074">Centers for Disease Control and Prevention. (2022b). <emphasis effect="italics">Diabetes risk factors</emphasis>. https://www.cdc.gov/diabetes/basics/risk-factors.html</para>
  <para id="para-00075">Chen, X., Feng, L., Yao, H., Yang, L., &amp; Qin, Y. (2021). Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis. <emphasis effect="italics">PloS One</emphasis>, <emphasis effect="italics">16</emphasis>(2), e0246463. https://doi.org/10.1371/journal.pone.0246463</para>
  <para id="para-00076">Corcoran, C., &amp; Jacobs, T. F. (2022). <emphasis effect="italics">Metformin.</emphasis> StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK518983/</para>
  <para id="para-00077">Costello, R. A., Nicolas, S., &amp; Shivkumar, A. (2022). <emphasis effect="italics">Sulfonylureas</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK513225/</para>
  <para id="para-00078">DailyMed. (Updated September 6, 2020). <emphasis effect="italics">Acarbose tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c445953d-c20a-4b70-8173-009bffc5777b</para>
  <para id="para-00079">DailyMed. (Updated July 25, 2023). <emphasis effect="italics">Apidra (insulin glulisine) injection</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7af6a7a-8046-4fb4-99794ec4230b23aa</para>
  <para id="para-00080">DailyMed. (Updated December 21, 2022). <emphasis effect="italics">Byetta injection. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f</para>
  <para id="para-00081">DailyMed. (Updated May 4, 2023). <emphasis effect="italics">Bydureon injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5</para>
  <para id="para-00082">DailyMed. (Updated January 5, 2023). <emphasis effect="italics">Diazoxide oral solution.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1863e5d-f2b5-2e47-e053-2a95a90af475</para>
  <para id="para-00083">DailyMed. (Updated March 24, 2023). <emphasis effect="italics">Dulaglutide injection. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309</para>
  <para id="para-00084">DailyMed. (Updated May 8, 2023). <emphasis effect="italics">Farxiga (Dapagliflozin) tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69</para>
  <para id="para-00085">DailyMed. (Updated December 2, 2021). <emphasis effect="italics">Glimepiride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60e9397e-83b9-489e-9683-6f87e458bbaa</para>
  <para id="para-00086">DailyMed. (Updated November 5, 2022). <emphasis effect="italics">Glipizide tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5565ccec-8000-48ab-a6af-37eca2d8c993</para>
  <para id="para-00087">DailyMed. (Updated November 10, 2021). <emphasis effect="italics">Glucagon kit.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c431b4-5618-4ff4-954e-4c0fbfed67b6</para>
  <para id="para-00088">DailyMed. (Updated March 14, 2022). <emphasis effect="italics">Glyburide and metformin tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7010b662-8b34-49ce-8e5b-73dee0821a60</para>
  <para id="para-00089">DailyMed. (Updated December 27, 2019). <emphasis effect="italics">Glyburide tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c391b11-68e9-4040-8408-56b43ee853f5</para>
  <para id="para-00090">DailyMed. (Updated July 21, 2023). <emphasis effect="italics">Humalog injection. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f</para>
  <para id="para-00091">DailyMed. (Updated March 7, 2023). <emphasis effect="italics">Humulin N injection</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6edd793-440b-40c2-96b5-c16133b7a921</para>
  <para id="para-00092">DailyMed. (Updated January 30, 2023). <emphasis effect="italics">Humulin R injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b519bd83-038c-4ec5-a231-a51ec5cc291f</para>
  <para id="para-00093">DailyMed. (Updated August 7, 2023). <emphasis effect="italics">Janumet (Sitagliptin and metformin) tablet. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d19c7ed0-ad5c-426e-b2df-722508f97d67</para>
  <para id="para-00094">DailyMed. (Updated July 31, 2023). <emphasis effect="italics">Januvia (Sitagliptin) tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01</para>
  <para id="para-00095">DailyMed. (Updated June 22, 2023). <emphasis effect="italics">Jardiance (Empagliflozin) tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565</para>
  <para id="para-00096">DailyMed. (Updated June 17, 2022). <emphasis effect="italics">Lantus (insulin glargine) injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a</para>
  <para id="para-00097">DailyMed. (Updated December 8, 2022). <emphasis effect="italics">Levemir insulin injection</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d38d65c1-25bf-401d-9c7e-a2c3222da8af</para>
  <para id="para-00098">DailyMed. (Updated July 21, 2023). <emphasis effect="italics">Lispro injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97d5e596-aae1-42c9-ae89-c3780959c467</para>
  <para id="para-00099">DailyMed. (Updated May 24, 2023). <emphasis effect="italics">Metformin HCL tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bdd2faa-2125-4139-b958-196393e31b7e</para>
  <para id="para-00100">DailyMed. (Updated October 23, 2019). <emphasis effect="italics">Miglitol tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=192e6ed7-9e8c-4772-9e3b-5912a1c63a31</para>
  <para id="para-00101">DailyMed. (Updated July 28, 2023). <emphasis effect="italics">Mounjaro injection. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0</para>
  <para id="para-00102">DailyMed. (Updated November 23, 2022). <emphasis effect="italics">Novolin N insulin injection. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82f1445c-b2c6-445a-82cf-ba8825fac776</para>
  <para id="para-00103">DailyMed. (Updated November 23, 2022). <emphasis effect="italics">Novolin R insulin injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aee7f1f3-612c-4027-8ce9-4fd1f41eed71</para>
  <para id="para-00104">DailyMed. (Updated February 28, 2023). <emphasis effect="italics">Novolog insulin injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a1e73a2-3009-40d0-876c-b4cb2be56fc5</para>
  <para id="para-00105">DailyMed. (Updated October 7, 2022). <emphasis effect="italics">Ozempic, Semaglutide injection. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79</para>
  <para id="para-00106">DailyMed. (Updated February 14, 2022). <emphasis effect="italics">Pioglitazone HCL tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df</para>
  <para id="para-00107">DailyMed. (Updated December 15, 2022). <emphasis effect="italics">Repaglinide tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68064989-47ea-4ed5-a20e-43c4ef6ec271</para>
  <para id="para-00108">DailyMed. (Updated April 14, 2023). <emphasis effect="italics">Sitagliptin tablet. </emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9519812-a5b0-1a19-e053-6294a90a471d </para>
  <para id="para-00109">DailyMed. (Updated December 18, 2019). <emphasis effect="italics">Symlinpen, Pramlintide acetate injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff</para>
  <para id="para-00110">DailyMed. (Updated June 26, 2023). <emphasis effect="italics">Tradjenta (Linagliptin) tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c797ea5c-cab7-494b-9044-27eba0cfe40f</para>
  <para id="para-00111">DailyMed. (Updated July 1, 2022). <emphasis effect="italics">Tresiba insulin injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=456c5e87-3dfd-46fa-8ac0-c6128d4c97c6</para>
  <para id="para-00112">DailyMed. (Updated July 5, 2023). <emphasis effect="italics">Victoza, Liraglutide injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4</para>
  <para id="para-00113">DailyMed. (Updated July 10, 2023). <emphasis effect="italics">Xultrophy (Insulin degludec and liraglutide) injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21335fe4-d395-4501-ac2a-2f20d7520da9</para>
  <para id="para-00114">Dhatariya K., Corsino L., &amp; Umpierrez, G. E. (2020). Management of diabetes and hyperglycemia in hospitalized patients. In K. R. Feingold, B. Anawalt, M. R. Blackman, et al. (Eds.), <emphasis effect="italics">Endotext.</emphasis> MDText.com. https://www.ncbi.nlm.nih.gov/books/NBK279093/</para>
  <para id="para-00115">Dhillon S. (2019). Dapagliflozin: A review in type 2 diabetes. <emphasis effect="italics">Drugs</emphasis>, <emphasis effect="italics">79</emphasis>(10), 1135–1146. https://doi.org/10.1007/s40265-019-01148-3</para>
  <para id="para-00116">Diabetes.co.uk. (2023). <emphasis effect="italics">Fixed dose insulin therapy.</emphasis> https://www.diabetes.co.uk/insulin/fixed-dose-therapy.html</para>
  <para id="para-00117">Dilworth, L., Facey, A., &amp; Omoruyi, F. (2021). Diabetes mellitus and its metabolic complications: The role of adipose tissues. <emphasis effect="italics">International Journal of Molecular Science.22</emphasis>,(14) 7644. https://doi.org/10.3390/ijms22147644</para>
  <para id="para-00118">Dimakos, J., Cui, Y., Platt, R. W., Renoux, C., Filion, K. B., &amp; Douros, A. (2023). Concomitant use of Sulfonylureas and β-blockers and the risk of severe hypoglycemia among patients with type 2 diabetes: A population-based cohort study. <emphasis effect="italics">Diabetes Care</emphasis>; <emphasis effect="italics">46</emphasis> (2): 377–383. https://doi.org/10.2337/dc22-1584</para>
  <para id="para-00119">Eggleton, J. S., &amp; Jialal, I. (2023). <emphasis effect="italics">Thiazolidinediones.</emphasis> StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551656/</para>
  <para id="para-00120">Feingold, K. R. (2022). Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. In K. R. Feingold, B. Anawalt, M. R. Blackman, et al. (Eds.), <emphasis effect="italics">Endotext.</emphasis> MDText.com. https://www.ncbi.nlm.nih.gov/books/NBK279141/</para>
  <para id="para-00121">Gharabaghi, M. A. M. Z., Rezvanfar, M. R., Saeedi, N., Aghajani, F., Alirezaei, M., Yarahmadi, P., &amp; Nakhostin-Ansari, A. (2022). Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: A double-blind, randomized clinical trial. <emphasis effect="italics">Clinical Diabetes and Endocrinology</emphasis>, <emphasis effect="italics">8</emphasis>(1), 5. https://doi.org/10.1186/s40842-022-00142-1</para>
  <para id="para-00122">He, M., Deng, M., Wang, J., Fan, P., Wang, Y., Zhao, X., He, Y., Shi, B., &amp; Sui, J. (2021). Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia. <emphasis effect="italics">Experimental and Therapeutic Medicine</emphasis>, <emphasis effect="italics">21</emphasis>(3), 217. https://doi.org/10.3892/etm.2021.9649</para>
  <para id="para-00123">He, Z., Gao, Y., Lieu, L., Afrin, S., Cao, J., Michael, N. J., Dong, Y., Sun, J., Guo, H., &amp; Williams, K. W. (2019). Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons—Implications for energy balance and glucose control. <emphasis effect="italics">Molecular Metabolism</emphasis>, <emphasis effect="italics">28</emphasis>, 120–134. https://doi.org/10.1016/j.molmet.2019.07.008</para>
  <para id="para-00124">Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., Skyler, J. S., Snoek, F. J., Weinstock, R. S., &amp; Peters, A. L. (2021). The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <emphasis effect="italics">Diabetologia</emphasis>, <emphasis effect="italics">64</emphasis>(12), 2609–2652. https://doi.org/10.1007/s00125-021-05568-3</para>
  <para id="para-00125">Institute for Safe Medication Practices. (2019). <emphasis effect="italics">Independent double checks: Worth the effort if used judiciously and properly</emphasis>. https://www.ismp.org/resources/independent-double-checks-worth-effort-if-used-judiciously-and-properly</para>
  <para id="para-00126">Jódar, E., Romera, I., Wang, Q., Roche, S. L., &amp; García-Pérez, L. E. (2022). Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials. <emphasis effect="italics">Diabetes, Obesity &amp; Metabolism</emphasis>, <emphasis effect="italics">24</emphasis>(4), 631–640. https://doi.org/10.1111/dom.14615</para>
  <para id="para-00127">Kalra, S., Das, A. K., Priya, G., Ghosh, S., Mehrotra, R. N., Das, S., Shah, P., Bajaj, S., Deshmukh, V., Sanyal, D., Chandrasekaran, S., Khandelwal, D., Joshi, A., Nair, T., Eliana, F., Permana, H., Fariduddin, M. D., Shrestha, P. K., Shrestha, D., Kahandawa, S., Shaikh, K. (2020). Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. <emphasis effect="italics">Journal of Family Medicine and Primary Care</emphasis>, <emphasis effect="italics">9</emphasis>(11), 5450–5457. https://doi.org/10.4103/jfmpc.jfmpc_843_20</para>
  <para id="para-00128">Kasina, S. V. S. K., &amp; Baradhi, K. M. (2022). <emphasis effect="italics">Dipeptidyl peptidase IV (DPP IV) inhibitors. </emphasis>StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK542331/</para>
  <para id="para-00129">Maikawa, C. L., Smith, A. A. A., Zou, L., Roth, G. A., Gale, E. C., Stapleton, L. M., Baker, S. W., Mann, J. L., Yu, A. C., Correa, S., Grosskopf, A. K., Liong, C. S., Meis, C. M., Chan, D., Troxell, M., Maahs, D. M., Buckingham, B. A., Webber, M. J., &amp; Appel, E. A. (2020). A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs. <emphasis effect="italics">Nature Biomedical Engineering</emphasis>, <emphasis effect="italics">4</emphasis>(5), 507–517. https://doi.org/10.1038/s41551-020-0555-4</para>
  <para id="para-00130">Mathew, P., &amp; Thoppil, D. (2022). <emphasis effect="italics">Hypoglycemia</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK534841/</para>
  <para id="para-00131">Migdal, A. L., Fortin-Leung, C., Pasquel, F., Wang, H., Peng, L., &amp; Umpierrez, G. E. (2021). Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 diabetes: Who can slide? <emphasis effect="italics">Journal of Hospital Medicine, 16</emphasis>(8), 462–468. https://doi.org/10.12788/jhm.3654</para>
  <para id="para-00132">Morris, C. H., &amp; Baker J. (2022). <emphasis effect="italics">Glucagon</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK559195/</para>
  <para id="para-00133">NIH National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Tests &amp; diagnosis for gestational diabetes. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational/tests-diagnosis</para>
  <para id="para-00134">National Library of Medicine. (2022a). <emphasis effect="italics">Glimepiride</emphasis>. Medline Plus<emphasis effect="italics">. </emphasis>https://medlineplus.gov/druginfo/meds/a696016.html#brand-name-1</para>
  <para id="para-00135">National Library of Medicine. (2022b). <emphasis effect="italics">Glipizide</emphasis>. Medline Plus. https://medlineplus.gov/druginfo/meds/a684060.html</para>
  <para id="para-00136">National Library of Medicine. (2022c). <emphasis effect="italics">Glyburide</emphasis>. Medline Plus. https://medlineplus.gov/druginfo/meds/a684058.html#brand-name-1</para>
  <para id="para-00137">Padda, I. S., Mahtani, A. U., &amp; Parmar, M. (2022). <emphasis effect="italics">Sodium-glucose transport protein 2 (SGLT2) inhibitors.</emphasis> StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK576405/</para>
  <para id="para-00138">Rubin, R., Khanna, N. R., &amp; McIver, L. A. (2022). <emphasis effect="italics">Aspart insulin</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK500030/</para>
  <para id="para-00139">Sapra, A., &amp; Bhandari, P. (2023). <emphasis effect="italics">Diabetes</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551501/</para>
  <para id="para-00140">Shuster, D. L., Shireman, L. M., Ma, X., Shen, D. D., Flood Nichols, S. K., Ahmed, M. S., Clark, S., Caritis, S., Venkataramanan, R., Haas, D. M., Quinney, S. K., Haneline, L. S., Tita, A. T., Manuck, T. A., Thummel, K. E., Brown, L. M., Ren, Z., Brown, Z., Easterling, T. R., &amp; Hebert, M. F. (2020). Pharmacodynamics of glyburide, metformin, and glyburide/metformin combination therapy in the treatment of gestational diabetes mellitus. <emphasis effect="italics">Clinical Pharmacology and Therapeutics</emphasis>, <emphasis effect="italics">107</emphasis>(6), 1362–1372. https://doi.org/10.1002/cpt.1749</para>
  <para id="para-00141">Sizar, O., Podder, V., &amp; Talati, R. (2022). <emphasis effect="italics">Empagliflozin</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK532925/</para>
  <para id="para-00142">Smits, M. M., &amp; Van Raalte, D. H. (2021). Safety of semaglutide. <emphasis effect="italics">Frontiers in Endocrinology</emphasis>, <emphasis effect="italics">12</emphasis>, 645563. https://doi.org/10.3389/fendo.2021.645563</para>
  <para id="para-00143">Thota, S., &amp; Akbar, A. (2022). <emphasis effect="italics">Insulin</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK560688/</para>
  <para id="para-00144">U.S. Food &amp; Drug Administration. (2023). FDA approves first cellular therapy to treat patients with type 1 diabetes. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-type-1-diabetes</para>
  <para id="para-00145">World Health Organization. (n.d.). Mean fasting blood glucose. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2380</para>
  <para id="para-00146">Wysham, C. H., Rosenstock, J., Vetter, M. L., Wang, H., Hardy, E., &amp; Iqbal, N. (2020). Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. <emphasis effect="italics">BMJ Open Diabetes Research &amp; Care</emphasis>, <emphasis effect="italics">8</emphasis>(1), e000773. https://doi.org/10.1136/bmjdrc-2019-000773</para>
  <para id="para-00147">Yale School of Medicine. (2022). For diabetic patients on glucophage and glucovance: How to take your oral diabetes medications containing metformin after you receive iodinated contrast dye for a CT scan. https://medicine.yale.edu/diagnosticradiology/patientcare/policies/glucophage/</para>
  <para id="para-00148">Zhou, X. J., Ding, L., Liu, J. X., Su, L. Q., Dong, J. J., &amp; Liao, L. (2019). Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: A randomized clinical trial. <emphasis effect="italics">Endocrine Connections</emphasis>, <emphasis effect="italics">8</emphasis>(4), 318–325. https://doi.org/10.1530/EC-18-0523</para>
  </section>
  </content>
  <glossary>
  <definition id="def-00001"><term>pheochromocytoma</term> <meaning>a rare non-cancerous tumor that develops in the adrenal gland that causes an excessive release of adrenal hormones</meaning></definition>
  </glossary>
  </document>